CDR609 / CDR-Life - LARVOL DELTA

Preclinical Evaluation of CDR609, an LGR5-Directed T Cell Engager, Supporting Clinical Development for Gastrointestinal Cancers (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Gastrointestinal Cancer • Oncology • Solid Tumor

Mechanistic insights into the pharmacology of CDR609 support high potential as a targeted immunotherapy (AACR 2026) - P1 | "CDR609 is a first-in-class T cell engager for the treatment of LGR5-expressing solid tumors, based on the same M-gager® format as CDR404 currently in Phase I (NCT06402201). Its activity at low E:T ratios supports efficacy in immunologically "cold" tumors, while cetuximab combination enhances potency via LGR5 upregulation. These data support the high potential of CDR609 in hard-to-treat cancers like CRC and studies are ongoing to enable initiation of a first-in-human clinical trial."

First-in-human • IO biomarker • Late-breaking abstract • Colorectal Cancer • Oncology • Solid Tumor • GZMB • KRAS • LGR5 • MSI

CDR609: A First-in-Class LGR5-targeted T Cell Engager for treatment of Colorectal Cancer and other solid tumors (AACR-NCI-EORTC 2025) - P1 | "CDR609 is a first-in-class T cell engager (TCE) for the treatment of LGR5-expressing solid tumors, based on the same M-gager® format as CDR404 (Phase I, NCT06402201). CDR609 also shows high specificity for LGR5, and an overall safe profile in the presence of normal human cells. Future studies will include in vivo efficacy testing and a broader range of cellular assays using ex vivo patient-derived tissues and cultured cells as part of the preclinical studies that will be included in the IND application."

IO biomarker • Colorectal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • CD69 • CD8 • GZMB • IFNG • IL2RA • LGR5

…CDR-Life is also presenting a poster on CDR609, the company’s newest T cell engager clinical candidate that targets LGR5, a highly cancer-specific cell surface antigen widely expressed on common solid tumors (Businesswire) - "The data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics...."

Preclinical • Colorectal Cancer

CDR-Life Announces CDR609 as New T-Cell Engager Clinical Candidate Targeting LGR5, a Highly Cancer-specific Surface Antigen Widely Expressed on Common Solid Tumor (Businesswire) - "CDR-Life...announced CDR609 as its next clinical candidate. CDR609 is a novel TCE targeting LGR5, a surface antigen that presents a compelling opportunity for broad, tumor-specific therapeutic intervention in solid tumors....The company plans to initiate IND-enabling studies in the second half of 2025."

IND • Pipeline update • Solid Tumor